QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia
To evaluate the efficacy and safety of QL0911 in cancer treatment-induced thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood. Sometimes, thrombocytopenia is a side effect of cancer treatment.
Cancer Treatment-Induced Thrombocytopenia
DRUG: QL0911|DRUG: QL0911 plus Placebo|DRUG: Placebo
The proportion of treatment responders., Randomization up to 80 days
Duration from the commencement of treatment to a platelet count ≥100×109/L, Randomization up to 30 days|Proportion of subjects who could complete chemotherapy without dose modification and rescue therapy, Randomization up to 150 days|Number of adverse events (AEs)/serious adverse events (SAEs), Randomization up to 150 days
To evaluate the efficacy and safety of QL0911 in cancer treatment-induced thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood. Sometimes, thrombocytopenia is a side effect of cancer treatment.